Who is the new Chief Marketing Officer at Innovent Biologics?

Innovent Biologics named Nageatte Ibrahim Chief Marketing Officer, announced April 16, 2024.

Which similar companies made leadership changes around the same time?

EBOS Group (April 29, 2024), YS Biopharma (May 7, 2024), Lifecore Biomedical (March 20, 2024) and Everest Medicines (March 18, 2024) also announced leadership changes within 45 days of Innovent Biologics.

Innovent Appoints Dr. Nageatte Ibrahim as Oncology CMO

PUBLIC · IVBXFApr 16, 2024

Position

Chief Marketing Officer

Company

Innovent Biologics

Nageatte Ibrahim

nageatte.ibrahim@innoventbio.com

SuzhouManufacturingBiotechnologyHealth CarePharmaceuticalPharmaceutical Manufacturing

Description

Innovent Biologics, Inc. announces the appointment of Dr. Nageatte Ibrahim as the Oncology Chief Medical Officer

Quick answer

Innovent Appoints Dr. Nageatte Ibrahim as Oncology CMO (April 16, 2024). Innovent Biologics is based in Suzhou, Jiangsu, China.

Who is the new Chief Marketing Officer at Innovent Biologics?: Innovent Biologics named Nageatte Ibrahim Chief Marketing Officer, announced April 16, 2024.
What did Innovent Biologics announce on April 16, 2024?: Innovent Biologics, Inc. announces the appointment of Dr. Nageatte Ibrahim as the Oncology Chief Medical Officer
What does Innovent Biologics do?: Established in 2011, Innovent is committed to developing, manufacturing and commercializing high quality innovative medicines for the treatment of major diseases such as cancer.
Where is Innovent Biologics based?: Innovent Biologics is based in Suzhou, Jiangsu, China.
Which similar companies made leadership changes around the same time?: EBOS Group (April 29, 2024), YS Biopharma (May 7, 2024), Lifecore Biomedical (March 20, 2024) and Everest Medicines (March 18, 2024) also announced leadership changes within 45 days of Innovent Biologics.

Source: Fundz verified event record.

Other recent leadership changes in Pharmaceutical and Pharmaceutical Manufacturing

Executive moves at companies in the same sectors within 45 days, from Fundz verified event records.

EBOS Group Appoints Alistair Gray as Chief Financial Officer (April 29, 2024)
YS Biopharma Appoints Dave Chenn as Interim CEO and Hui Shao as Co-CEO and CBO (May 7, 2024)
Lifecore Biomedical Appoints Paul Josephs as CEO (March 20, 2024)
Everest Medicines Appoints Sandra Zeng as Chief Medical Officer and Rico Liang as Chief Product Officer (March 18, 2024)
Teva Pharmaceutical Industries Ltd. Appoints Matthew Shields as Executive Vice President of Teva Global Operations (May 15, 2024)
Elanco Promotes Shiv O’Neill to General Counsel (March 6, 2024)

Who to call at Innovent Biologics, and when

A new leader at Innovent Biologics brings new priorities and often new vendors. The first weeks are when they listen.

An alert the day Innovent Biologics raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Innovent Biologics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Innovent Biologics. With Fundz connected, it knows.

Watch Fundz in

See plan options

Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Innovent Biologics

Location

Suzhou, Jiangsu, China

About

Established in 2011, Innovent is committed to developing, manufacturing and commercializing high quality innovative medicines for the treatment of major diseases such as cancer. On 31 October, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK. Since its inception, Innovent has developed a fully-integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities. Leveraging the platform, the company has built a robust pipeline of 23 valuable assets in the fields of cancer, metabolic, autoimmune diseases and other major therapeutic areas, with 4 products, TYVYT® (sintilimab injection), BYVASDA® (bevacizumab injection), SULINNO® (adalimumab injection), HALPRYZA® (rituximab injection) officially approved for marketing in China, 5 assets in Phase III or pivotal clinical trials, and additional 14 molecules in to clinical trials. TYVYT® was included in the National Reimbursement Drug List (NRDL) in 2019 as the only PD-1 in that year and was also the first PD-1 inhibitor included in NRDL historically.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Innovent Biologics changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Book a demo Explore plans

Related People

Fei

Likely contact at this company

••••••••@••••••••

See Fei's verified email →

Create an account to reveal verified emails

Predictive Intelligence

Strategic

ML-powered predictions for Innovent Biologics's next move

Learn about Strategic plan

Innovent Biologics changed its leadership. Fundz had it the day it was filed, with the decision-maker at the company attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

Show me how a recruiter uses this Or see plans and pricing →

5 screens from a live account. No signup.